Author:
Scarpa Lorenza,Buxbaum Sabine,Kendler Dorota,Fink Katharina,Bektic Jasmin,Gruber Leonhard,Decristoforo Clemens,Uprimny Christian,Lukas Peter,Horninger Wolfgang,Virgolini Irene
Funder
University of Innsbruck and Medical University of Innsbruck
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine
Reference43 articles.
1. National Cancer Institute, Surveillance Epidemiology and End Results, SEER stat fact sheets: prostate. Available from: http://seer.cancer.gov/statfacts/htlm/prost.htlm .
2. Khuntia D, Reddy CA, Mahadevan A, et al. Recurrence free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate specific antigen era: what should we expect? Cancer. 2004;100:1283–92.
3. Vallabhajosula A, Goldsmith SJ, Hamacher KA, et al. Prediction of myelotoxicity based on bone marrow radiationabsorbed dose: radioimmunotherapy studies using 90Y‐ and 177Lu‐labeled J591 antibodies specific for prostate specific membrane antigen. J Nucl Med. 2005;46:850–8.
4. Zechmann CM, Afshar-Oromieh A, Armor T, et al. Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280–92.
5. Vallabhajosula S, Nikolopoulou A, Babich JW, et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. SJ2. J Nucl Med. 2014;55:1791–8.
Cited by
86 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献